ArticleHeliyon2022
Machine learning-based prognosis signature for survival prediction of patients with clear cell renal cell carcinoma.
Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- From Genes to Proteins: The Indispensable Role of Proteogenomics in Advancing Clear Cell Renal Cell Carcinoma Research.International journal of molecular sciences · 2026Review
- Development and validation of a machine learning model for predicting distant metastasis in patients with renal cell carcinoma: a population-based study.World journal of surgical oncology · 2026Article
- Diagnostic value of an interpretable machine learning model based on clinical ultrasound features for follicular thyroid carcinoma.Quantitative imaging in medicine and surgery · 2024Article
- Development and validation of a machine learning-based prognostic risk stratification model for acute ischemic stroke.Scientific reports · 2023Article
- Prediction of Distant Metastasis in Renal Cell Carcinoma Using Machine Learning Algorithms: A Multicenter Cohort Study.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The sole clinicopathological characteristic is not enough for the prediction of survival of patients with clear cell renal cell carcinoma (ccRCC). However, the survival prediction model constructed by machine learning technology for patients with ccRCC using clinicopathological features is rarely reported yet. In this study, a total of 5878 patients diagnosed as ccRCC from four independent patient cohorts were recruited. The least absolute shrinkage and selection operator analysis was implemented to identify optimal clinicopathological characteristics and calculate each coefficient to construct the prognosis model. In addition, weighted gene co-expression network and gene enrichment analysis associated with risk score were also carried out. Three clinicopathologic features were selected for the construction of the prognosis risk score model as the prognostic factors of ccRCC, including tumor size, tumor grade, and tumor stage. In the CPTAC (Clinical Proteomic Tumor Analysis Consortium) cohort, the General cohort, the SEER (Surveillance, Epidemiology, and End Results) cohort, and the Huashan cohort, patients with high-risk score had worse clinical outcomes than patients with low-risk score (hazard ratio 5.15, 4.64, 3.96, and 5.15, respectively). Further functional enrichment analysis demonstrated that our machine learning-based risk score was significantly connected with some cell proliferation-related pathways, consisting of DNA repair, cell division, and cell cycle. In summary, we developed and validated a machine learning-based prognosis prediction model, which might contribute to clinical decision-making for patients with ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.